In August 2001 Sally Laden, the article's author, arranged for GSK to buy 500 reprints of the article; 300 were for Keller and 200 for Zachary Hawkins of GSK's Paxil Product Management team, to be distributed to the company's neuroscience sales force [REF].
The memo said that paroxetine was "significantly more effective than placebo" on certain outcomes.